McKesson Corporation (MCK, a giant in healthcare distribution, recently unveiled full-year fiscal 2025 results that saw its top line surge past $359 billion, representing a substantial +16.22% increase year-over-year. This record revenue figure underscores the sheer scale and operational efficiency of the company's vast distribution network, particularly impressive within the notoriously thin-margin healthcare sector.
This robust financial performance provides a critical backdrop for understanding McKesson's concurrent strategic maneuvers, most notably the planned spin-off of its Medical-Surgical Solutions segment. The move signals a deliberate pivot towards optimizing its portfolio and sharpening its focus on higher-growth, higher-margin areas, a strategy that could redefine its long-term earnings profile and competitive stance in the evolving healthcare landscape.
Recent Financial Performance Highlights#
McKesson's fiscal year ending March 31, 2025, demonstrated significant operational strength. Beyond the headline revenue figure of $359.05 billion (Source: Monexa AI, the company reported a net income of $3.29 billion, an increase of +9.76% compared to the $3.00 billion reported in FY2024 (Source: Monexa AI. This growth in profitability, while trailing the revenue surge, reflects the inherent dynamics of the distribution business where cost of revenue constitutes the vast majority of sales.
Professional Market Analysis Platform
Unlock institutional-grade data with a free Monexa workspace. Upgrade whenever you need the full AI and DCF toolkit—your 7-day Pro trial starts after checkout.
Earnings per share (EPS) also saw healthy growth. The reported EPS for FY2025 stood at $25.71 (Source: Monexa AI, contributing to a trailing twelve months (TTM) EPS of $26.32 (Source: Monexa AI. This TTM EPS figure is notably higher than the $22.91 reported for FY2024, representing a +14.87% year-over-year increase in diluted EPS (Source: Monexa AI. The company also demonstrated strong cash generation, with net cash provided by operating activities reaching $6.08 billion in FY2025, a significant +41.05% increase from the $4.31 billion in FY2024. Free cash flow mirrored this strength, rising +67.77% from $3.63 billion in FY2024 to $6.08 billion in FY2025 (Source: Monexa AI.
Despite the impressive top-line growth, it's important to examine profitability ratios. The gross profit margin slightly compressed from 4.07% in FY2024 to 3.71% in FY2025. Similarly, the net income margin saw a minor dip from 0.97% to 0.92% over the same period (Source: Monexa AI. This underscores the persistent margin pressure characteristic of the healthcare distribution sector, making strategic cost management and focus on higher-margin business segments crucial for future profitability expansion.
| Metric | FY2025 Value | FY2024 Value | YoY Change | Source |
|---|---|---|---|---|
| Revenue | $359.05B | $308.95B | +16.22% | Monexa AI |
| Net Income | $3.29B | $3.00B | +9.76% | Monexa AI |
| Diluted EPS | $25.71 | $22.91 | +14.87% | Monexa AI |
| Operating Cash Flow | $6.08B | $4.31B | +41.05% | Monexa AI |
| Free Cash Flow | $6.08B | $3.63B | +67.77% | Monexa AI |
| Gross Profit Margin | 3.71% | 4.07% | -0.36 pp | Monexa AI |
| Net Income Margin | 0.92% | 0.97% | -0.05 pp | Monexa AI |
Strategic Realignment: The Medical-Surgical Spin-Off#
On May 8, 2025, alongside its strong earnings report, McKesson announced a significant strategic move: the planned spin-off of its Medical-Surgical Solutions segment (Source: Forbes.com. This segment generated approximately $11.4 billion in revenue during FY2025 (Source: Forbes.com, representing about 3.2% of the company's total revenue. While a relatively small portion of the overall business, this segment includes distribution of medical supplies, lab equipment, and other products to physician offices, labs, and post-acute care settings.
Monexa for Analysts
Go deeper on MCK
Open the MCK command center with real-time data, filings, and AI analysis. Upgrade inside Monexa to trigger your 7-day Pro trial whenever you’re ready.
The strategic rationale behind the spin-off is multi-faceted. It is primarily aimed at allowing McKesson to sharpen its focus and allocate capital more effectively towards its higher-growth, higher-margin businesses, particularly its Oncology and Biopharma Solutions segments. These areas are seen as having greater potential for profitability expansion and strategic investment in areas like specialty pharmaceuticals and related services. By separating the Medical-Surgical business, which has experienced more modest growth compared to other parts of the portfolio, McKesson believes it can unlock greater shareholder value by allowing both entities to pursue tailored growth strategies and capital structures (Source: Forbes.com. The separation is currently anticipated to be completed by late 2025.
This move is not without precedent in the industry, as large, diversified healthcare companies often evaluate their portfolio composition to optimize performance and capitalize on specific market opportunities. The success of the spin-off will depend on various factors, including market conditions at the time of separation, the ability of the new entity (